Document:

Form of Subscription Agent Agreement

 Exhibit 10.24 
 FORM OF SUBSCRIPTION AGENT AGREEMENT 
 THIS SUBSCRIPTION AGENT AGREEMENT
(“Agreement”) between Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (“Continental”), is dated as of
February [    ], 2009. 
 1. Appointment. 
 (a) The Company is making an offer (the “Rights Offering”) to its stockholders of record at the close of business on
February [    ], 2009 (the “Record Date”), of non-transferable subscription rights (the “Rights”) to purchase up to an aggregate of
[            ] shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of
$[            ] per Right (the “Subscription Price”). The term “Subscribed” shall mean submitted for purchase from the Company by a stockholder in
accordance with the terms of the Rights Offering, and the term “Subscription” shall mean any such submission. 
 (b) The Rights Offering will expire on March [    ], 2009 at 5:00 p.m. New York City Time (the “Expiration Time”), unless the Company shall have extended the period of time for which the Rights Offering
is open, in its sole discretion for up to 45 days, in which event the term “Expiration Time” shall mean the latest time and date at which the Rights Offering, as so extended by the Company from time to time, shall expire. 
 (c) The Company filed a Registration Statement on Form S-1 (File No. 333-155491) relating to the Rights Offering with the United States
Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended, on November 19, 2008 (the “Registration Statement”). The terms of the Rights Offer are more fully described in the
Prospectus (the “Prospectus”) forming part of the Registration Statement as such Registration Statement may be declared effective by the SEC. A copy of the Prospectus is attached hereto as Exhibit 1. All terms used and not
defined herein shall have the same meaning as in the Prospectus. Promptly after the Record Date, the Company will provide Continental with a list of holders of Common Stock as of the Record Date (the “Record Stockholders List”)

 (d) The Company hereby appoints Continental to act as subscription agent (the “Subscription Agent”) for
the Rights Offering in accordance with and subject to the following terms and conditions. 
 2. Subscription of Rights. 
 (a) The Rights are evidenced by subscription rights certificates (the “Certificates”), a copy of the form of which is
attached hereto as Exhibit 2. The Certificates entitle the holders to subscribe, upon payment of the Subscription Price, for shares of Common Stock at the rate of two shares per Right evidenced by a Certificate (the “Basic
Subscription Right”). No fractional shares will be issued. 

 (b) The Rights Offering includes an over-subscription right entitling the subscribing
stockholders who exercise their Basic Subscription Right in full to subscribe and pay the Subscription Price for additional Rights representing up to an additional amount equal to up to 400% of the shares for which such holder was otherwise entitled
to subscribe (the “Over-Subscription Right”). Reference is made to the Prospectus for a complete description of the Basic Subscription Right and the Over-Subscription Right and the allocation thereof. 
 3. Duties of Subscription Agent. As Subscription Agent, Continental is authorized and directed to: 
 (a) Issue the Certificates in accordance with this Agreement in the names of the holders of the Common Stock of record or other nominees
on the Record Date, keep such records as are necessary for the purpose of recording such issuance, and furnish a copy of such records to the Company. The Certificates may be signed on behalf of the Subscription Agent by the manual or facsimile
signature of a Vice President or Assistant Vice President of the Subscription Agent, or by the manual signature of any of its other authorized officers. 
 (b) Promptly after Continental receives the Record Stockholders List, Continental shall: 
 (i) mail or cause to be mailed, by first class mail, or deliver (which delivery may be done electronically through the facilities of the Depository Trust Company (“DTC”) or otherwise) to each holder of Common Stock of
record on the Record Date whose address of record is within the United States and Canada, (i) a Certificate evidencing the Rights to which such stockholder is entitled under the Rights Offering, (ii) a copy of the Prospectus and
(iii) a return envelope addressed to the Subscription Agent; and 
 (ii) mail or cause to be mailed, by air mail, to each
holder of Common Stock of record on the Record Date whose address of record is outside the United States and Canada, or is an A.P.O. or F.P.O. address, a copy of the Prospectus. Continental shall refrain from mailing Certificates issuable to any
holder of Common Stock of record on the Record Date whose address of record is outside the United States and Canada, or is an A.P.O. or F.P.O. address, and hold such Certificates for the account of such stockholder subject to such stockholder making
satisfactory arrangements with the Subscription Agent for the exercise of the Rights evidenced thereby, and follow the instructions of such stockholder for the exercise of such Rights if such instructions are received at or before 11:00 a.m., New
York City Time, on                         . 
 (c) Mail or deliver (which delivery may be done electronically through the facilities of DTC or otherwise) a copy of the Prospectus with
certificates for shares of Common Stock when such are issued to persons other than the registered holder of the Certificate. 
 (d) Accept Subscriptions upon the due exercise (including payment of the Subscription Price) on or prior to the Expiration Time of Rights in accordance with the terms of the Certificates and the Prospectus. 
 (e) Subject to the next sentence, accept Subscriptions from stockholders whose Certificates are alleged to have been lost, stolen or
destroyed upon receipt by Continental 

  

 2 

 
of an affidavit of theft, loss or destruction and a bond of indemnity in form and substance reasonably satisfactory to Continental, accompanied by payment of
the Subscription Price for the total number of Rights Subscribed for. Upon receipt of such affidavit and bond of indemnity and compliance with any other applicable requirements, stop orders shall be placed on said Certificates and Continental shall
withhold delivery of the Rights Subscribed for until after the Certificates have expired and it has been determined that the Rights evidenced by the Certificates have not otherwise been purported to have been exercised or otherwise surrendered.

 (f) Accept Subscriptions, without further authorization or direction from the Company, without procuring supporting legal
papers or other proof of authority to sign (including without limitation proof of appointment of a fiduciary or other person acting in a representative capacity), and without signatures of co-fiduciaries, co-representatives or any other person:

 (i) if the Certificate is registered in the name of a fiduciary and is executed by, and the Rights are to be issued in the
name of, such fiduciary; 
 (ii) if the Certificate is registered in the name of joint tenants and is executed by one of the
joint tenants, provided the certificate representing the Rights is issued in the names of, and is to be delivered to, such joint tenants; 
 (iii) if the Certificate is registered in the name of a corporation and is executed by a person in a manner which appears or purports to be done in the capacity of an officer, or agent thereof, provided the Rights are
to be issued in the name of such corporation; or 
 (iv) if the Certificate is registered in the name of an individual and is
executed by a person purporting to act as such individual’s executor, administrator or personal representative, provided, the Rights are to be registered in the name of the subscriber as executor or administrator of the estate of the deceased
registered holder and there is no evidence indicating the subscriber is not the duly authorized representative that he purports to be. 
 (g) Accept Subscriptions not accompanied by Certificates if submitted by a firm having membership in the New York Stock Exchange or another national securities exchange or by a commercial bank or trust company having
an office in the United States and accompanied by proper payment for the total number of Rights Subscribed for. 
 (h) Refer
to the Company, for specific instructions as to acceptance or rejection, Subscriptions received after the Expiration Time, Subscriptions not authorized to be accepted, and Subscriptions otherwise failing to comply with the requirements of the
Prospectus and the terms and conditions of the Certificates. 
 4. Acceptance of Subscriptions. Upon acceptance of a Subscription,
Continental shall from time to time during the offering: 
 (a) Hold all monies received in a dedicated, non-interest bearing
account for the benefit of the Company. Promptly following the Expiration Time, Continental shall, upon the receipt of the Distribution Letter in the form attached hereto as Exhibit 3 and executed by the Company and Maxim Group LLC,
distribute to the Company the funds from exercise of the Basic Subscription Rights and Over-Subscription Rights in such account and following the Expiration Date issue (in physical form or electronically through the facilities of DTC, in each case
in a manner approved by the Company) certificates for shares of Common Stock 

  

 3 

 
issuable with respect to Subscriptions that have been accepted. Continental will not be obligated to calculate or pay interest to any holder or any other
party claiming through a holder or otherwise. It is hereby agreed immediately following the effective date of the Subscription, immediately available funds, represented by certified check, money order, or wire transfer but not personal check, will
be deposited with Continental. In the event that the Rights Offering is not consummated because the Company (i) has cancelled or terminated the Rights Offering or (ii) is unable to raise a minimum of $2,500,000 (net of expenses) in the Rights
Offering prior to the Expiration Date (unless such minimum is waived or reduced by the Company’s board of directors and with the prior written consent of Maxim Group LLC (which consent will not be unreasonably withheld)), Continental shall,
upon the receipt of the Liquidation Letter in the form attached hereto as Exhibit 4 and executed by the Company and Maxim Group LLC, liquidate the segregated account in which the subscription monies were held as promptly as practicable and
distribute the funds to each respective subscribing stockholder who elected to exercise its Rights. 
 (b) Advise the Company
daily by facsimile transmission and confirm by letter to the attention of Anthony Squeglia (the “Company Representative”) as to the total number of shares of Common Stock Subscribed for, the total number of Rights partially
Subscribed for and the amount of funds received, with cumulative totals for each; and in addition advise the Company Representative, by telephone at (617) 559-0033, confirmed by facsimile transmission, of the amount of funds received identified
in accordance with (a) above, deposited, available or transferred in accordance with (a) above, with cumulative totals; and 
 (c) As promptly as possible but in any event on or before 3:30 p.m., New York City Time, on the first full business day following the Expiration Time, advise the Company Representative in accordance with
(b) above of the number of shares Subscribed for and the number of shares of Common Stock unsubscribed for. 
 5. Completion of
Rights Offering. Upon completion of the Rights Offering: 
 (a) Continental shall issue (in physical form or
electronically through the facilities of DTC, in each case in a manner approved by the Company) certificates for the Common Stock for which Subscriptions have been received. 
 (b) The Certificates may be physical certificates but may, as instructed by the Company be issued electronically through the facilities of
DTC. The Company shall appoint and have in office at all times a Transfer Agent and Registrar for the Certificates, which may be Continental and which shall keep books and records of the registration and transfers and exchanges of Certificates (such
books and records are hereinafter called the “Certificate Register”). The Company shall promptly notify the Transfer Agent and Registrar of the exercise of any Certificates. The Company shall promptly notify Continental of any
change in the Transfer Agent and Registrar of the Certificates. 
 (c) All Certificates issued upon any registration of
transfer or exchange of Certificates shall be the valid obligations of the Company, evidencing the same obligations, and entitled to the same benefits under this Agreement, as the Certificates surrendered for such registration of transfer or
exchange. 
 (d) For so long as this Agreement shall be in effect, the Company will reserve for issuance and keep available
free from preemptive rights a sufficient number of shares of Common Stock to permit the exercise in full of all Rights issued pursuant to the Rights Offering. Subject to the terms and conditions of this Agreement, Continental will request the
Transfer Agent for the Common Stock to issue (in physical form or electronically through the facilities of DTC, in each case in a manner approved by the Company) certificates evidencing the appropriate number of shares of Common Stock as required
from time to time in order to effectuate the Subscriptions. 
 (e) The Company shall take any and all action, including
without limitation obtaining the authorization, consent, lack of objection, registration or approval of any governmental authority, or the taking of any other action under the laws of the United States of 

  

 4 

 
America or any political subdivision thereof, to insure that all shares of Common Stock issuable upon the exercise of the Certificates at the time of
delivery of the certificates therefor (subject to payment of the Subscription Price) will be duly and validly issued and fully paid and non-assessable shares of Common Stock, free from all preemptive rights and taxes, liens, charges and security
interests created by or imposed upon the Company with respect thereto. 
 (f) The Company shall from time to time take all
action necessary or appropriate to obtain and keep effective all registrations, permits, consents and approvals of the SEC and any other governmental agency or authority and make such filings under Federal and state laws which may be necessary or
appropriate in connection with the issuance and delivery of Certificates or the issuance, sale, transfer and delivery of Common Stock issued upon exercise of Certificates. 
 6. Procedure for Discrepancies. Continental shall follow its regular procedures to attempt to reconcile any discrepancies between the number of
shares of Common Stock that any Certificate may indicate are to be issued to a stockholder and the number that the Record Stockholders List indicates may be issued to such stockholder. In any instance where Continental cannot reconcile such
discrepancies by following such procedures, Continental will consult with the Company for instructions as to the number of shares of Common Stock, if any, it is authorized to issue. In the absence of such instructions, Continental is authorized not
to issue any shares of Common Stock to such stockholder. 
 7. Procedure for Deficient Items. Continental shall examine the
Certificates received by it as Subscription Agent to ascertain whether they appear to have been properly completed and executed. In the event Continental determines that any Certificate does not appear to have been properly completed or executed, or
where the Certificates do not appear to be in proper form for Subscription, or any other irregularity in connection with the Subscription appears to exist, Continental shall follow, where possible, its regular procedures to attempt to cause such
irregularity to be corrected. Continental is not authorized to waive any irregularity in connection with the Subscription, unless Continental shall have received from the Company the Certificate which was delivered, duly dated and signed by an
authorized officer of the Company, indicating that any irregularity in such Certificate has been cured or waived and that such Certificate has been accepted by the Company. If any such irregularity is neither corrected nor waived, Continental will
return to the subscribing stockholder (at its option by either first class mail under a blanket surety bond or insurance protecting Continental and the Company from losses or liabilities arising out of the non-receipt or nondelivery of Certificates
or by registered mail insured separately for the value of such Certificates) to such stockholder’s address as set forth in the Subscription any Certificates surrendered in connection therewith and any other documents received with such
Certificates, and a letter of notice to be furnished by the Company explaining the reasons for the return of the Certificates and other documents. 
 8. Date/Time Stamp. Each document received by Continental relating to its duties hereunder shall be dated and time stamped when received. 
 9. Transfer Procedures. If certificates representing shares of Common Stock are to be delivered by Continental to a person other than the person in whose name a 
  

 5 

 
surrendered Certificate is registered, Continental shall issue no certificate for Common Stock until the Certificate so surrendered has been properly
endorsed (or otherwise put in proper form for transfer). 
 10. Tax Reporting. Should any issue arise regarding federal income tax
reporting or withholding, Continental shall take such action as the Company reasonably instructs in writing. 
 11. Termination. The
Company may terminate this Agreement at any time by so notifying Continental in writing. Continental may terminate this Agreement upon 60 days’ prior written notice to the Company. Upon any such termination, Continental shall be relieved and
discharged of any further responsibilities with respect to its duties hereunder. Upon payment of all Continental’s outstanding fees and expenses, Continental shall forward to the Company or its designee promptly any Certificate or other
document relating to Continental’s duties hereunder that Continental may receive after its appointment has so terminated. Sections 12, 13, 14 and 19 of this Agreement shall survive any termination of this Agreement. 
 12. Authorizations and Protections. As agent for the Company, Continental: 
 (a) shall have no duties or obligations other than those specifically set forth herein or as may subsequently be agreed to in writing by
Continental and the Company; 
 (b) shall have no obligation to issue any shares of Common Stock unless the Company shall have
provided a sufficient number of certificates for such Common Stock; 
 (c) shall be regarded as making no representations and
having no responsibilities as to the validity, sufficiency, value, or genuineness of any Certificates surrendered to Continental hereunder or shares of Common Stock issued in exchange therefor, and will not be required to or be responsible for and
will make no representations as to, the validity, sufficiency, value or genuineness of the Rights Offering; 
 (d) shall not
be obligated to take any legal action hereunder; if, however, Continental determines to take any legal action hereunder, and where the taking of such action might, in Continental’s judgment, subject or expose it to any expense or liability,
Continental shall not be required to act unless it shall have been furnished with an indemnity reasonably satisfactory to it; 
 (e) may rely on and shall be fully authorized and protected in acting or failing to act upon any certificate, instrument, opinion, notice, letter, telegram, telex, facsimile transmission or other document or security delivered to
Continental and believed by it to be genuine and to have been signed by the proper party or parties; 
 (f) shall not be
liable or responsible for any recital or statement contained in the Prospectus or any other documents relating thereto; 
 (g)
shall not be liable or responsible for any failure on the part of the Company to comply with any of its covenants and obligations relating to the Rights Offering, including without limitation obligations under applicable securities laws; 

 

 6 

 (h) may rely on and shall be fully authorized and protected in acting or failing to act
upon the written, telephonic or oral instructions of officers of the Company with respect to any matter relating to Continental acting as Subscription Agent covered by this Agreement (or supplementing or qualifying any such actions); 
 (i) may consult with counsel satisfactory to Continental, including internal counsel, and the advice of such counsel shall be full and
complete authorization and protection in respect of any action taken, suffered, or omitted by Continental hereunder in good faith and in reliance upon the advice of such counsel; and 
 (j) are not authorized, and shall have no obligation, to pay any brokers, dealers, or soliciting fees to any person. 
 13. Indemnification. The Company agrees to indemnify Continental for, and hold it harmless from and against, any loss, liability, claim or expense
(“Loss”) arising out of or in connection with Continental’s performance of its duties under this Agreement or this appointment, including the costs and expenses of defending itself against any Loss or enforcing this Agreement,
except to the extent that such Loss shall have been determined by a court of competent jurisdiction to be a result of Continental’s negligence or intentional misconduct. 
 14. Limitation of Liability. 
 (a) In the absence of negligence or intentional misconduct on its part, Continental shall not be liable for any action taken, suffered, or omitted by it or for any error of judgment made by it in the performance of its duties under this
Agreement. Anything in this agreement to the contrary notwithstanding, in no event shall Continental be liable for special, indirect, incidental or consequential loss or damage of any kind whatsoever (including but not limited to lost profits), even
if Continental has been advised of the likelihood of such damages and regardless of the form of action. Any liability of Continental will be limited to the amount of fees paid by the Company hereunder. 
 (b) In the event any question or dispute arises with respect to the proper interpretation of this Agreement or Continental’s duties
hereunder or the rights of the Company or of any holders surrendering certificates for shares of Common Stock pursuant to the Rights Offering, Continental shall not be required to act and shall not be held liable or responsible for refusing to act
until the question or dispute has been judicially settled (and Continental may, if it deems it advisable, but shall not be obligated to, file a suit in interpleader or for a declaratory judgment for such purpose) by final judgment rendered by a
court of competent jurisdiction, binding on all stockholders and parties interested in the matter which is no longer subject to review or appeal, or settled by a written document in form and substance satisfactory to Continental and executed by the
Company and each such stockholder and party. In addition, Continental may require for such purpose, but shall not be obligated to require, the execution of such written settlement by all the stockholders and all other parties that may have an
interest in the settlement. 
 15. Representations, Warranties and Covenants. The Company represents, warrants and covenants that
(a) it is duly incorporated, validly existing and in good standing under the 
  

 7 

 
laws of its jurisdiction of incorporation, (b) the making and consummation of the Rights Offering and the execution, delivery and performance of all
transactions contemplated thereby (including without limitation this Agreement) have been duly authorized by all necessary corporate action and will not result in a breach of or constitute a default under the articles of incorporation or bylaws of
the Company or any indenture, agreement or instrument to which either is a party or is bound, (c) this Agreement has been duly executed and delivered by the Company and constitutes a legal, valid, binding obligation of the Company, enforceable
against the Company in accordance with its terms, (d) the Rights Offering will comply in all material respects with all applicable requirements of law, and (e) to the best of their knowledge, there is no litigation pending or threatened as
of the date hereof in connection with the Rights Offering. 
 16. Notices. All notices, demands and other communications given
pursuant to the terms and provisions hereof shall be in writing, shall (except as provided for in Section 18 hereof) be deemed effective on the date of receipt, and may be sent by facsimile, overnight delivery services, or by certified or registered
mail, return receipt requested to: 
 If to the Company: 
 Pro-Pharmaceuticals, Inc. 
 7 Wells Avenue 
 Newton, Massachusetts 02459 
 Telephone: (617) 559-0033 
 Facsimile: (617) 928-3450 
 Attn: Anthony Squeglia 
 with a copy to: 
 Jonathan Guest 
 Greenberg Traurig, LLP 
 One International Place 
 Boston, Massachusetts 02110 
 Telephone: (617) 310-6000 
 Facsimile: (617) 310-6001 
 If to Continental: 
 Continental Stock Transfer & Trust Company 
 17 Battery Place, 8th Floor 
 New York, NY 10004 
 Telephone: (212) 845-3287 
 Facsimile: (212) 616-7616 
 Attn: Compliance Department 
 17. Specimen Signatures. Set forth in Exhibit 5 hereto is a list
of the names and specimen signatures of the persons authorized to act for the Company under this Agreement. The Secretary of the Company shall, from time to time, certify to Continental the names and signatures of any other persons authorized to act
for the Company, as the case may be, under this Agreement. 
  

 8 

 18. Instructions. Any instructions given to Continental orally, as permitted by any provision of
this Agreement, shall, upon the request of Continental, be confirmed in writing by the Company (which for these purposes only may be undertaken by e-mail transmission) as soon as practicable. Continental shall not be liable or responsible and shall
be fully authorized and protected for acting, or failing to act, in accordance with any oral instructions which do not conform with the written confirmation received in accordance with this Section. 
 19. Fees. Whether or not any Certificates are surrendered to Continental, for its services as Subscription Agent hereunder, the Company shall pay
to Continental a fee of Ten Thousand and no/100 Dollars ($10,000.00), together with reimbursement for reasonable out-of-pocket expenses. All amounts owed to Continental hereunder are due upon receipt of the invoice. 
 20. Force Majeure. Continental shall not be liable for any failure or delay arising out of conditions beyond its reasonable control including, but
not limited to, work stoppages, fires, civil disobedience, riots, rebellions, storms, electrical, mechanical, computer or communications facilities failures, acts of God or similar occurrences. 
 21. Miscellaneous. 
  
 (a) This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving effect to
conflict of laws, rules or principles. 
 (b) No provision of this Agreement may be amended, modified or waived, except in
writing signed by all of the parties hereto. 
 (c) Except as expressly set forth elsewhere in this Agreement, all notices,
instructions and communications under this Agreement shall be in writing, shall be effective upon receipt and shall be addressed as provided in Section 16 to such other address as a party hereto shall notify the other parties in writing.

 (d) In the event that any claim of inconsistency between this Agreement and the terms of the Rights Offering arise, as they
may from time to time be amended, the terms of the Rights Offering shall control, except with respect to Continental’s duties, liabilities and rights, including without limitation compensation and indemnification, which shall be controlled by
the terms of this Agreement. 
 (e) If any provision of this Agreement shall be held illegal, invalid, or unenforceable by any
court, this Agreement shall be construed and enforced as if such provision had not been contained herein and shall be deemed an Agreement among the parties hereto to the full extent permitted by applicable law. 
 (f) This Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the respective successors and assigns of the
parties hereto. 
 (g) This Agreement may not be assigned by any party without the prior written consent of all parties.

  

 9 

 (h) Sections 12, 13, 14 and 19 hereof shall survive termination of this Agreement.

 (i) This Agreement may be executed in counterparts, each of which, when taken together, shall constitute one and the same
agreement, and each of which may be delivered by the parties by facsimile or other electronic transmission, which shall not impair the validity of such counterparts. 
 (Signature page follows) 
  

 10 

 Signature Page 
 to 
 Subscription Agent Agreement 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized officers as of the day and year above written. 

 

	
	 PRO-PHARMACEUTICALS, INC.

	
	 By:                                       
                                         
                

	 Name:

	 Title:

	
	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Subscription Agent
	
	 By:                                       
                                         
                

	 Name:

	 Title:

 Exhibit 1    Prospectus 
 Exhibit 2    Form of Subscription Rights Certificate 
 Exhibit 3    Distribution
Letter 
 Exhibit 4    Liquidation Letter 
 Exhibit 5    List of Authorized Representatives 
  

 11 

 Exhibit 1 
 to 
 Subscription Agent Agreement 
 Prospectus 
  

 12 

 Exhibit 2 
 to 
 Subscription Agent Agreement 
 Form of Subscription Rights Certificate 
  

 13 

 Exhibit 3 
 to 
 Subscription Agent Agreement 
 Form of Distribution Letter 
 [Letterhead of Company] 
 [Insert date] 
 Continental Stock Transfer & Trust
Company 
 17 Battery Place 
 New York, New York 10004 

Attn: [                    ] 
 Re: Trust Account No. [    ] Termination Letter 
 Ladies
and Gentlemen: 
 Pursuant to Section __ of the Subscription Agent Agreement between Pro-Pharmaceuticals, Inc. (“Company”) and
Continental Stock Transfer & Trust Company (“Subscription Agent”), dated as of February __, 2009 (“Subscription Agent Agreement”), this is to advise you that the Company has raised the minimum amount in its Rights Offering
(as defined in the Subscription Agent Agreement) or the waiver of such minimum has been authorized and approved by the Board of Directors of the Company on or about [______]. You are hereby directed and authorized to transfer the subscription funds
held in the segregated account immediately in accordance with the terms of the Instruction Letter. 
  

			
	Very truly yours,
	
	PRO-PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:
	
	MAXIM GROUP LLC
		
	By:	 	 
		 	Name:
		 	Title:

 Exhibit 4 
 to 
 Subscription Agent Agreement 
 Form of Liquidation Letter 
 [Letterhead of Company] 
 [Insert date] 
 Continental Stock Transfer & Trust
Company 
 17 Battery Place 
 New York, New York 10004 

Attn: [                     ] 
 Re: Trust Account No. [     ] Termination Letter 
 Ladies
and Gentlemen: 
 Pursuant to Section __ of the Subscription Agent Agreement between Pro-Pharmaceuticals, Inc. (“Company”) and
Continental Stock Transfer & Trust Company (“Subscription Agent”), dated as of February __, 2009 (“Subscription Agent Agreement”), this is to advise you that the Company has been unable to consummate its Rights Offering (as
defined in the Subscription Agent Agreement. 
 In accordance with the terms of the Subscription Agent Agreement, we hereby authorize you to
commence liquidation of the segregated account in which the subscription monies were held as promptly as practicable to stockholders who elected to exercise their Rights. You shall commence distribution of such funds in accordance with the terms of
the segregated account and you shall oversee the distribution of such funds. Upon the payment of all the funds in the segregated account, your obligations under the Trust Agreement shall be terminated. 
  

			
	Very truly yours,
	
	PRO-PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:
	
	MAXIM GROUP LLC
		
	By:	 	 
		 	Name:
		 	Title:

 Exhibit 5 
 to 
 Subscription Agent Agreement 
 List of Authorized Representatives 
  

			
	 Authorized

 Representative
	 	 Specimen Signature

		
		 	/s/
		 	 
		
		 	/s/
		 	 

  

 16License Agreement dated November 25, 2008

 Exhibit 10.25 
 LICENSE AGREEMENT 
 This LICENSE AGREEMENT
(this “Agreement”) is entered into as of the 25th day of November, 2008 (the “Effective Date”), between Pro-Pharmaceuticals,
Inc., a Nevada corporation (“Licensor”) and Medi-Pharmaceuticals, Inc., a Nevada corporation (“Licensee”). 
 The parties
hereto, intending to be legally bound, hereby agree as follows: 
 Section 1. Definitions. 
  

	 	1.1	“Intellectual Property” means any and all patents, research data, chemical or molecular designs and other intellectual rights of any kind or nature now or hereafter
owned by or licensed to Licensor (in the case of intellectual property rights licensed to Licensor by a third party, to the full extent that Licensor is authorized to grant sublicenses with respect thereto) relating to Licensor’s library of
proprietary polysaccharides, together with any and all software, online (Internet) content, web-based content, documentation or other tangible or electronic embodiments of any of the foregoing. 

  

	 	1.2	“Licensed Rights” means the Intellectual Property and Licensee Improvements, as they may exist from time to time. 

  

	 	1.3	“Licensee Improvements” means any invention, idea, know-how, addition, extension, or modification conceived, developed or invented by Licensee that is primarily and
materially dependent upon and utilizes the Intellectual Property, whether or not patentable or otherwise protectable as intellectual property. 

  

	 	1.4	“Net Revenues” means the revenues actually received by Licensee solely from the sale, use, display, license or other economic exploitation of the Licensed Rights
strictly within the scope and in accordance with the license described in Section 2.1 hereof, less (i) third party marketing and sales expenses and distribution costs (ii) shipping and taxes (if a part of the gross sales price
so invoiced), and (iii) net of refunds, discounts, or other financial settlements which are given by Licensee in the ordinary course. 

 Section 2. License and Compensation. 
  

	 	2.1	License. Licensor hereby grants to Licensee an irrevocable (except as provided in sections 4.1 and 4.2 hereof), exclusive, worldwide perpetual license to use the Licensed
Rights solely and strictly in the evaluation, clinical development, marketing and otherwise commercially exploiting, alone or in combination with other drugs, of products, regiments and procedures for pharmaceutical activity and/or clinical benefit
in the prevention and/or the cure of heart diseases. 

  

	 	2.2	Advance Payment. Subject to the terms and conditions of this Agreement, in consideration of the grant of the License, Licensee shall pay Licensor, on or before May 30,
2009, a one-time advance payment in cash of One Million Dollars ($1,000,000.00) (the “Advance Payment”). 

	 	2.3	Royalty. Subject to the terms and conditions of this Agreement, during the term of this Agreement, Licensee shall pay to Licensor a royalty equal to five percent (5%) of
the Net Revenues, except that such royalty shall be increased to ten percent (10%) of the Net Revenues realized by Licensee from a Licensed Right based on a divisional patent and a DMF (based on a GMD) obtained by Licensor, at its option, and
licensed to Licensee hereunder. All such royalty payments shall be payable quarterly on or before the fifteenth (15th) day after the quarter during which the Net Revenues giving rise to such royalty payment were generated. In the event of any
refunds, credits, discounts or other financial settlement by Licensee in favor of any customer or in the event a credit card charge is denied or not paid by the credit card issuer, in respect to any Net Revenues for which royalty payments have been
paid or are payable hereunder, Licensor hereby authorizes Licensee to deduct and retain from royalties subsequently payable the amount of royalties attributable to such refunds, credits, discounts, or other financial settlement or failure to receive
credit card payments for any reason. All payments to Licensor shall be accompanied by an accounting of the basis for such payment, identifying the source and amount of applicable revenue so received by the Licensee. The royalty payable to Licensor
under this Agreement shall terminate and cease immediately upon termination of this Agreement for any reason whatsoever. 

 Section 3.
Related Matters. 
  

	 	3.1	Delivery of Embodiments of the Intellectual Property. Licensor shall deliver to Licensee within ten (10) business days after the date hereof, in such form and on such
media as the parties may agree, all software, documentation or electronic or tangible embodiments of the Intellectual Property that have been created, developed or acquired by Licensor as of the date hereof. Licensor shall deliver or otherwise make
available to Licensee such software, documentation or electronic or tangible embodiments promptly after any request is made by Licensee with respect to any particular item that Licensor has not theretofore delivered or otherwise made available to
Licensee. 

  

	 	3.2	Infringement by Third Parties. If any party becomes aware of any product or activity of any third party that may involve infringement or violation of any Licensed Rights,
then such party shall promptly notify the other party in writing of the possible infringement or violation. Licensee may in its sole discretion decide whether to take action or not to prosecute such infringement. If Licensee elects to take action,
Licensor shall reasonably cooperate therewith, including by joining as a party. In such regard, Licensor shall, upon reasonable notice, use its best efforts to have any of its employees, officers, directors, managers, agents and other
representatives testify when requested by the Licensee and, on reasonable notice, shall use its best efforts to make available to the Licensee all relevant records, papers, information, samples, specimens and the like. 

  

	 	    	 If the Licensee does not, within ninety (90) days after receipt of notice of the possible infringement, commence action directed toward restraining or
enjoining 

	 	 
such infringement, Licensor may take such legally permissible action as it deems necessary or appropriate to enforce the Licensor’s and Licensee’s
rights and restrain such infringement at Licensor’s expense. If Licensor elects to take action, Licensee shall reasonably cooperate therewith, including by joining as a party if requested. 

  

	 	3.3	Claims Against the Parties. If at any time a claim is made or an action is brought against Licensee, its affiliates or customers, or Licensor, its affiliates or assigns by a
third party alleging infringement of any patent or other intellectual property right by reason of Licensee’s exercise of the Licensed Rights, Licensee shall promptly inform Licensor upon receiving notice of such claim. Licensor and Licensee
shall confer together to consider appropriate actions for avoiding infringement of such third party’s patent or of defending such claim or action. Licensee shall defend, indemnify and hold Licensor and its officers, directors, shareholders,
agents, employees and assigns (collectively. “Indemnified Parties”) harmless from and against all claims, damages or other liabilities asserted by or payable to third parties, including settlements (and reasonable attorneys’ fees and
costs incurred by the Indemnified Parties) on account thereof. 

  

	 	3.4	Warranty. Licensor hereby represents and warrants to Licensee that none of the Licensed Rights violates the intellectual property rights of any third party whatsoever.

 Section 4. Termination. 
  

	 	4.1	Termination of License. Licensor may terminate this Agreement and the license granted hereunder solely (a) if the Advance Payment is not timely made or (b) upon the
permanent cessation of substantially all of Licensee’s business pertaining to the Licensed Rights. Until such termination, Licensor shall not engage in any effort to commercialize the Intellectual Property in competition with Licensee.

  

	 	4.2	Effect of Termination. Upon termination of this Agreement, the license granted hereby shall terminate and Licensee shall immediately cease to exercise the Licensed Rights.
Within thirty (30) days after termination, Licensee shall return to Licensor or, if so instructed by the Licensor, destroy all copies of documentation in Licensee’s possession at the time of termination relating to the Licensed Rights.
Upon Licensor’s request, Licensee shall certify to Licensor in writing that, to the best of Licensee’s knowledge, Licensee has complied with this Section 4.2. 

  

	 	4.3	Survival. Sections 1 (Definitions), 3.4 (Warranty), 4.2 (Effect of Termination), and 5 (General Provisions) hereof, shall survive any expiration or termination of this
Agreement. 

 Section 5. General Provisions. 
  

	 	5.1	Relationship of the Parties. Nothing in this Agreement is to be construed as creating an agency, partnership, or joint venture relationship between Licensor and Licensee.

  

	 	5.2	Entire Agreement. This Agreement represents the entire agreement between the Licensor and Licensee with respect to the subject matter hereof and shall supersede all prior
agreements and communications of the parties, oral or written. 

  

	 	5.3	Amendment, Waiver and Instructions. No amendment to, or waiver of, any provision of this Agreement shall be effective unless in writing and signed by both parties. The waiver
by any party of any breach or default shall not constitute a waiver of any different or subsequent breach or default. 

  

	 	5.4	Governing Law and Jurisdiction. This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts without regard to the
conflicts of laws principles thereof. 

  

	 	5.5	Successors and Assigns. This Agreement and the license granted hereunder may not be assigned by Licensee, in whole or in part, without the prior written consent of the
Licensor, unless the assignee explicitly assumes the obligations of Licensee hereunder to Licensor’s reasonable satisfaction, and may be assigned by Licensee without Licensor’s consent to a successor to all or substantially all the assets
and business of Licensee. Notwithstanding the foregoing sentence, Licensee may create limited licenses to its manufacturers and others to the extent Licensee determines that such limited license is necessary or appropriate in its efforts to
commercialize the Licensed Rights. This Agreement may be assigned by Licensor without the consent of Licensee. Subject to the foregoing, this Agreement shall be binding upon, and inure to the benefit of, the permitted successors and assigns of each
party. 

  

	 	5.6	Notices. All notices, requests, consents and other communications which are required or permitted hereunder shall be in writing, and shall be delivered by registered U.S.
mail, postage prepaid (effective upon receipt) at the addresses set forth on the signature page. Notice of change of address shall be given in the same manner as other communications. 

  

	 	5.7	Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable for any reason, such invalidity, illegality or unenforceability shall not
affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 

  

	 	5.8	 Taxes. Licensee is solely responsible for the payment of any taxes (including sales or use taxes, intangible taxes and property taxes and any taxes which may
be owing in respect of the transactions enabled through use of the Licensed Rights) 

	 	 
resulting from Licensee’s acceptance of this Agreement and possession or exercise of the Licensed Rights, exclusive of taxes based on the
Licensor’s net income. 

  

	 	5.9	Headings. The section headings contained in this Agreement are included for convenience only, and shall not limit or otherwise affect the terms of this Agreement.

  

	 	5.10	Counterparts. This Agreement may be executed in two counterparts, both of which taken together shall constitute a single instrument. Execution and delivery of this Agreement
may be evidenced by facsimile transmission. 

  

									
	Pro-Pharmaceuticals, Inc.	 		 	Medi-Pharmaceuticals, Inc.
					
	By:	 	/s/    Anthony Squeglia	 		 	By:	 	/s/    David Platt
	Name:	 	Anthony Squeglia	 		 	Name:	 	David Platt
	Title:	 	Chief Financial Officer	 		 	Title:	 	President

 Pro-Pharmaceuticals, Inc. 
 7 Wells Avenue 
 Newton, Massachusetts 02459 
 December 15, 2008 
 Mr. Frank J. Garofalo 
 President 
 Medi-Pharmaceuticals, Inc. 
 c/o Pro-Pharmaceuticals, Inc. 
 7 Wells Avenue 
 Newton,
MA 02459 
 Dear Frank: 
 This letter is intended to clarify
certain matters in connection with the License Agreement, dated November 25, 2008, by and between Pro-Pharmaceuticals, Inc. and Medi-Pharmaceuticals, Inc., respectively the Licensor and Licensee under the Agreement. Capitalized terms in this
letter have the meanings given them in the Agreement. 
 1. The parties acknowledge that as of the Effective Date galactose-branched polysaccharides
(“G-B Polysaccharides”), whether developed or under development, constitutes the item(s) of Intellectual Property subject to the license granted under Section 2.1 of the Agreement (the “License”). The foregoing does not
preclude the parties from identifying additional matters, whether future developments of G-B Polysaccharides or otherwise, that constitute Intellectual Property subject to the License. 
 2. To the extent the compositions and their manufacturing process of any G-B Polysaccharides are covered by one or more existing or future patents owned by, or patent applications in prosecution by, Licensor and
within the scope of the Intellectual Property, or referred to in Drug Master File (“DMF”) filed by Licensor with the U.S. Food and Drug Administration, Licensee may refer, in any application or other document it submits to a regulatory
agency (e.g., in connection with pre-clinical studies to screen and establish proof of concept), to, as applicable, such patent(s), patent application(s) after publication thereof, or DMF. 
 3. Licensee may file one or more continuations-in-part with the U.S. Patent and Trademark Office or foreign patent agencies based on Licensee Improvements arising from
Licensor patents or patent applications within the scope of the Intellectual Property, including with respect any use of G-B Polysaccharides. 
 4. As of the
Effective Date, there was no software, documentation or electronic or tangible embodiments of G-B Polysaccharrides to be delivered pursuant to Section 3.1 of the Agreement. Section 3.1 creates an obligation to deliver embodiments of
Intellectual Property only when and if such embodiments exist. 

 5. For avoidance of confusion, the Advance Payment obligation under Section 2.2 exists whether or not a delivery of
any embodiments of Intellectual Property occurs on or before May 30, 2009. 
 Please indicate your assent to the foregoing by signing below and
returning a signed copy of this letter to our records. 
  

	
	Very truly yours,
	
	/s/    Anthony D. Squeglia
	 Anthony D. Squeglia
 Chief Financial
Officer

  

			
	 Assented to:
  
 Medi-Pharmaceuticals, Inc.

		
	By:	 	/s/    Frank J. Garofalo
		 	Frank J. Garofalo, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]